Written questions by Strathern.

If his Department will publish data on the number of (a) fathers who have accessed perinatal mental health services and (b) maternity outreach clinics that offer (i) evidence-based mental health assessments and (ii) signposting.

The information requested is not held centrally at this level of detail. The Government is committed to improving the support available to mothers, fathers, and partners who experience mental health difficulties, including postnatal depression, during the perinatal period.Fathers and partners of women accessing specialist perinatal mental health services and maternal mental health services should be offered an evidence-based assessment for their mental health and signposted to sources of support as required. This can include NHS Talking Therapies services, which are available for anyone who needs support with their mental health. People can refer themselves online via the National Health Service website or by contacting their general practice.In addition, in January 2025, the Department announced £126 million for the continuation of the Family Hubs and Start for Life programme in 2025/26 in 75 local authorities with high levels of deprivation. This includes £36.5 million for bespoke perinatal mental health and parent-infant relationship support, including for fathers.

What steps his Department is taking to ensure that NHS services (a) engage with new fathers and (b) record their details alongside the mothers in their baby's health records.

I refer the Hon. Member to the answer I gave to the Hon. Member for Livingston on 31 March 2025 to Question 38280.

If he will make an assessment of the potential benefits of making prostate cancer screening mandatory.

Screening for prostate cancer is currently not recommended by the UK National Screening Committees (UK NSC). This is because of the inaccuracy of the current best test, called the Prostate Specific Antigen (PSA). A PSA-based screening programme could harm some men as many would be diagnosed with a cancer that would not have caused them problems during their life. This would lead to additional tests and treatments which can also have harmful side effects, such as sexual dysfunction and incontinence.The UK NSC regularly reviews its recommendations, and the evidence review for prostate cancer screening is underway and plans to report within the UK NSC’s three-year work plan.The evidence review includes modelling the clinical effectiveness and cost of several approaches to prostate cancer screening, including different potential ways of screening the whole population from 40 years of age onwards, and targeted screening aimed at groups of people identified as being at higher than average risk, such as black men or men with a family history of cancer.

What recent discussions he has had on the provision of Enhurtu to Her2 low metastatic breast cancer patients.

The Department’s ministers and officials have had a number of recent meetings at which the issue of the availability of Enhertu for the treatment of HER2 low metastatic breast cancer has been discussed, including with Breast Cancer Now and other campaigners.The Government wants patients to be able to benefit from access to innovative and effective new treatments such as Enhertu at a price that fairly reflects the benefits that they bring to patients, and does not displace funding for other valuable treatments and services. The National Institute for Health and Care Excellence and NHS England have been clear with the companies that the price represents the main barrier to access to Enhertu for patients with HER2 low breast cancer, and we encourage the companies to come forward with an improved commercial offer.